SENSUS HEALTHCARE INC (SRTS) Stock Fundamental Analysis
NASDAQ:SRTS - US81728J1097 - Common Stock
3.25 USD
-0.02 (-0.61%)
3.25 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to SRTS. SRTS was compared to 185 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for SRTS as it has an excellent financial health rating, but there are worries on the profitability. SRTS has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
SRTS had negative earnings in the past year.
In the past year SRTS had a positive cash flow from operations.
SRTS had positive earnings in 4 of the past 5 years.
SRTS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of SRTS (-1.44%) is better than 68.65% of its industry peers.
With a decent Return On Equity value of -1.63%, SRTS is doing good in the industry, outperforming 70.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.44% | ||
| ROE | -1.63% | ||
| ROIC | N/A |
ROA(3y)18.11%
ROA(5y)8.54%
ROE(3y)21.11%
ROE(5y)9.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SRTS's Profit Margin has been stable in the last couple of years.
In the last couple of years the Operating Margin of SRTS has grown nicely.
Looking at the Gross Margin, with a value of 52.19%, SRTS is in line with its industry, outperforming 45.41% of the companies in the same industry.
SRTS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SRTS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 52.19% |
OM growth 3Y8.29%
OM growth 5YN/A
PM growth 3Y1.43%
PM growth 5YN/A
GM growth 3Y-2.39%
GM growth 5Y-1.93%
2. Health
2.1 Basic Checks
SRTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SRTS has been increased compared to 1 year ago.
Compared to 5 years ago, SRTS has about the same amount of shares outstanding.
SRTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
SRTS has an Altman-Z score of 6.45. This indicates that SRTS is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of SRTS (6.45) is better than 85.41% of its industry peers.
There is no outstanding debt for SRTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.45 |
ROIC/WACCN/A
WACC8.9%
2.3 Liquidity
A Current Ratio of 8.14 indicates that SRTS has no problem at all paying its short term obligations.
SRTS's Current ratio of 8.14 is amongst the best of the industry. SRTS outperforms 88.65% of its industry peers.
SRTS has a Quick Ratio of 5.79. This indicates that SRTS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.79, SRTS belongs to the top of the industry, outperforming 85.41% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.14 | ||
| Quick Ratio | 5.79 |
3. Growth
3.1 Past
The earnings per share for SRTS have decreased strongly by -114.63% in the last year.
The Earnings Per Share has been growing by 18.56% on average over the past years. This is quite good.
Looking at the last year, SRTS shows a small growth in Revenue. The Revenue has grown by 3.29% in the last year.
The Revenue has been growing by 8.93% on average over the past years. This is quite good.
EPS 1Y (TTM)-114.63%
EPS 3Y18.56%
EPS 5YN/A
EPS Q2Q%-160%
Revenue 1Y (TTM)3.29%
Revenue growth 3Y15.63%
Revenue growth 5Y8.93%
Sales Q2Q%-20.82%
3.2 Future
The Earnings Per Share is expected to grow by 11.64% on average over the next years. This is quite good.
Based on estimates for the next years, SRTS will show a quite strong growth in Revenue. The Revenue will grow by 14.67% on average per year.
EPS Next Y-131.62%
EPS Next 2Y1.25%
EPS Next 3Y13.61%
EPS Next 5Y11.64%
Revenue Next Year-12.96%
Revenue Next 2Y7.75%
Revenue Next 3Y14.69%
Revenue Next 5Y14.67%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SRTS. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 7.93, the valuation of SRTS can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SRTS indicates a rather cheap valuation: SRTS is cheaper than 96.76% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.81, SRTS is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.93 |
4.2 Price Multiples
91.35% of the companies in the same industry are more expensive than SRTS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.3 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SRTS's earnings are expected to grow with 13.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.25%
EPS Next 3Y13.61%
5. Dividend
5.1 Amount
SRTS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.25
-0.02 (-0.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners26.71%
Inst Owner Change33.31%
Ins Owners16.6%
Ins Owner Change0.02%
Market Cap53.43M
Analysts81.82
Price Target8.16 (151.08%)
Short Float %6.04%
Short Ratio6.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-443.8%
Min EPS beat(2)-561.36%
Max EPS beat(2)-326.24%
EPS beat(4)1
Avg EPS beat(4)-32.54%
Min EPS beat(4)-561.36%
Max EPS beat(4)786.28%
EPS beat(8)4
Avg EPS beat(8)32.29%
EPS beat(12)5
Avg EPS beat(12)8.22%
EPS beat(16)8
Avg EPS beat(16)22.58%
Revenue beat(2)1
Avg Revenue beat(2)-4.91%
Min Revenue beat(2)-22.89%
Max Revenue beat(2)13.08%
Revenue beat(4)3
Avg Revenue beat(4)13.83%
Min Revenue beat(4)-22.89%
Max Revenue beat(4)47%
Revenue beat(8)6
Avg Revenue beat(8)26.85%
Revenue beat(12)6
Avg Revenue beat(12)11.41%
Revenue beat(16)9
Avg Revenue beat(16)14%
PT rev (1m)-28.89%
PT rev (3m)-33.33%
EPS NQ rev (1m)-136.11%
EPS NQ rev (3m)-143.33%
EPS NY rev (1m)-212.73%
EPS NY rev (3m)-138.04%
Revenue NQ rev (1m)-34.97%
Revenue NQ rev (3m)-41.29%
Revenue NY rev (1m)-19.41%
Revenue NY rev (3m)-17.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.93 | ||
| P/S | 1.42 | ||
| P/FCF | 15.3 | ||
| P/OCF | 14.98 | ||
| P/B | 1.03 | ||
| P/tB | 1.03 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.06
EYN/A
EPS(NY)0.41
Fwd EY12.62%
FCF(TTM)0.21
FCFY6.54%
OCF(TTM)0.22
OCFY6.67%
SpS2.28
BVpS3.17
TBVpS3.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.44% | ||
| ROE | -1.63% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 52.19% | ||
| FCFM | 9.3% |
ROA(3y)18.11%
ROA(5y)8.54%
ROE(3y)21.11%
ROE(5y)9.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y8.29%
OM growth 5YN/A
PM growth 3Y1.43%
PM growth 5YN/A
GM growth 3Y-2.39%
GM growth 5Y-1.93%
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 13.73% | ||
| Cap/Sales | 0.2% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.14 | ||
| Quick Ratio | 5.79 | ||
| Altman-Z | 6.45 |
F-Score5
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)54.52%
Cap/Depr(5y)46.98%
Cap/Sales(3y)0.65%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-114.63%
EPS 3Y18.56%
EPS 5YN/A
EPS Q2Q%-160%
EPS Next Y-131.62%
EPS Next 2Y1.25%
EPS Next 3Y13.61%
EPS Next 5Y11.64%
Revenue 1Y (TTM)3.29%
Revenue growth 3Y15.63%
Revenue growth 5Y8.93%
Sales Q2Q%-20.82%
Revenue Next Year-12.96%
Revenue Next 2Y7.75%
Revenue Next 3Y14.69%
Revenue Next 5Y14.67%
EBIT growth 1Y-116.01%
EBIT growth 3Y25.22%
EBIT growth 5YN/A
EBIT Next Year-43.52%
EBIT Next 3Y29.92%
EBIT Next 5Y-27.34%
FCF growth 1Y129.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.61%
OCF growth 3YN/A
OCF growth 5YN/A